Sun Pharma gets CDSCO Panel nod to manufacture, market Progesterone SR Tablet
New Delhi: The drug major Sun Pharma has got green signal from the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) to manufacture and market the Progesterone Sustained Release (SR) Tablets (200/300/400mg).
Sustained Release (SR) Tablets are designed to release a drug in the body slowly over an extended period of time. It allows delivery of a specific drug at a programmed rate that leads to drug delivery for a prolonged period of time.
Progesterone is a hormone used for a variety of functions, including contraception, control of abnormal uterine bleeding, maintenance of pregnancy, and prevention of endometrial hyperplasia.
Progesterone binds and activates its nuclear receptor, PR, which plays an important part in the signaling of stimuli that maintain the endometrium during its preparation for pregnancy. Progesterone may prevent pregnancy by changing the consistency of cervical mucus to be unfavorable for sperm penetration, and by inhibiting follicle-stimulating hormone (FSH), which normally causes ovulation.
Exogenous progesterone supplementation is given for treatment of secondary amenorrhea, dysfunctional uterine bleeding, and endometriosis, for management of luteal phase deficiency, for preventing preterm delivery and also to prevent endometrial hyperplasia.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.